Patent Application
20110177069
The present invention relates to an inducer of chondrocyte proliferation and differentiation or an agent for increasing cartilage matrix production stimulating chondrogenesis, which comprises RANKL-binding molecules that accelerate differentiation and maturation of prechondrocytes and/or mesenchymal stem cells. The present invention also relates to a method of using the inducer to differentiate prechondrocytes and/or mesenchymal stem cells or to increase cartilage matrix production. Further, the present invention relates to a method for screening for a substance that binds to and transmits a signal to RANKL to differentiate and proliferate prechondrocytes and/or mesenchymal stem cells or a substance that increases cartilage matrix production, the substance obtained by such screening method, and a pharmaceutical composition comprising the obtained substance.
Cartilage is composed of chondrocytes and a large quantity of intercellular cartilage matrices. Cartilage is classified into three types based on differences in cartilage matrix properties: i.e., hyaline cartilage constituting skeletal primordias at the fetal stage or major parts of articular cartilage; fibrocartilage comprising type I collagen in the matrix; and elastic cartilage existing in the auricula and in the epiglottis (see Shih Hone no Kagaku (Bone Biology), written and edited by Tateo Suda et al., Ishiyaku Pub, Inc. and KouSoshiki Kenkyu Handbook (Handbook of Hard Tissue Research), Division of Hard Tissue Research, Graduate School, Matsumoto Dental University).
Chondrocytes as constituents originate from pluripotent undifferentiated mesenchymal stem cells, and undifferentiated mesenchymal stem cells are aggregated by the Sox transcription factor (SRY-related HMG box-containing gene) 9 and converted into prechondrocytes. The prechondrocytes secrete a group of matrices such as type II collagen, type IX collagen, and proteoglycan to be converted into cartilage matrices. Consequently cartilage matrices increase, cells are individualized, and differentiated into chondroblasts through synergistic action with transcription factors such as Sox5 and Sox6. Further, transcription factor expression (i.e., of the runt-related gene 2 (Runx2)) is suppressed and expression of ERG/C-1-1 (i.e., the ets related gene) is accelerated in immature chondroblasts, and differentiation into permanent chondrocytes advances (see Hone/nankotsu taisha to chumoku no hone shikkan (Bone/cartilage metabolism and critical bone diseases), Toshio Matsumoto (ed.), Yodosha Co., Ltd. and Inada et al., Dev. Dyn 214: 279, 1999). It was reported that enlarged chondrocytes would lead to enhanced expression of type X collagen.
There are two patterns for the processes of cartilage growth. One of them is interstitial growth, in which cells differentiated, into chondrocytes and surrounded by the cartilage matrix proliferate through cell division. Each chondrocyte secretes a matrix, and cartilage tissue is then enlarged.
The other growth pattern is appositional growth caused by the perichondrium. Cartilage tissue is covered with a perichondrium except for the articular surface of the articular cartilage. The strong perichondrium is constituted of fibroblasts, but is similar to chondrocytes in the inner layer, thus the difference between fibroblasts and chondrocytes is unclear. Perichondrium cells in the inner layer proliferate while gradually changing into circular forms, and such cells further a secrete cartilage matrix and grow outwardly.
In general, the outside of the perichondrium of the cartilage tissue is in contact with connective tissue that is rich in blood vessels and nerves, although the inside thereof does not contain blood vessels or nerves. When the cartilage is damaged inside, accordingly, it cannot be repaired by undifferentiated stem cells, cytokines, and so on. In addition, the capacity of the chondrocytes for mitotic proliferation is poor, and self-repair of chondrocytes is very difficult.
The method to repair a articular cartilage is a topical injection in cartilage matrix, a implantation of cultured bone marrow mesenchymal stem cells to prepare autologous chondrocytes, or an impregnating of matrix disc with chondrocyte growth factors. Transforming growth factor (TGF-β1), insulin-like growth factor (IGF-1), basic fibroblast growth factor (bFGF), PTH-related peptide (PTHrP) that are highly homologous to the 13 N-terminal amino acids of PTH, hepatocyte growth factor (HGF), and bone morphogenetic protein (BMP) belonging to TGF-β superfamily have been reported as chondrocyte growth factors. BMP and TGF-β may induce to lose the function of chondrocytes after implantation due to calcification in article cartilage, because these factors have some important effects, such as aggregation of undifferentiated mesenchymal stem cells, and inhibitory effect on terminal chondrocytic differentiation in addition to the effect on chondrocyte growth.
Osteoclast differentiation factor (i.e., the receptor activator of NF-κB ligand (RANKL)) is a membrane-binding protein of tumor necrosis factor (TNF) family that is induced on osteoblasts/stromal cells by bone resorption factors, and is necessary for differentiation and maturation of osteoclasts (see Yasuda et al., Proc. Natl. Acad. Sci., U.S.A., 95: 3597, 1998 and Lacey et al., Cell 93: 165, 1998). Research focusing on RANKL/RANK/OPG, including a receptor (i.e., the receptor activator of NF-κB (RANK)) and a decoy receptor (i.e., the osteoprotegerin (OPG)), has led to elucidation of the control mechanism for osteoclast differentiation and maturation in vivo, and the correlation between these 3 molecules and metabolic bone diseases has also become elucidated (see Suda et al., Endocr Rev, 20: 345, 1999).
A correlation between RANKL and differentiation and proliferation of prechondrocytes and/or mesenchymal stem cells has been unknown.
The present invention is intended to provide a method for inducing chondrocyte proliferation, and differentiation or increasing cartilage matrix production via administration of an effective amount of molecules that have capacity of binding to RANKL, act on prechondrocytes and/or mesenchymal stem cells, accelerate chondrocytes differentiation, proliferation, and maturation of these cells, enhance chondrocyte differentiation, and induce chondrocyte proliferation. The present invention is also intended to provide a pharmaceutical composition including the molecules used for inducing chondrocyte proliferation and differentiation or for increasing cartilage matrix production.
The present inventors discovered that a variety of proteins, peptides, peptoids, and molecules that act on RANKL induced proliferation and differentiation of chondrocytes or acceleration of cartilage matrix production from prechondrocytes and/or mesenchymal stem cells. Specifically, the present invention is as follows.
[1] A pharmaceutical composition used for treatment or prevention of chondropathies comprising, as an active ingredient, a compound that acts on prechondrocytes and/or mesenchymal stem cells and induces at least one of: (a) acceleration of prechondrocyte and/or mesenchymal stem cell differentiation; (b) acceleration of prechondrocyte and/or mesenchymal stem cell proliferation; (c) acceleration of prechondrocyte and/or mesenchymal stem cell maturation; (d) enhancement of chondrocyte differentiation; and (e) chondrocyte proliferation.
[2] The pharmaceutical composition used for treatment or prevention of chondropathies according to [1], wherein the compound that acts on the prechondrocytes and/or mesenchymal stem cells and induces at least one of: (a) acceleration of prechondrocyte and/or mesenchymal stem cell differentiation; (b) acceleration of prechondrocyte and/or mesenchymal stem cell proliferation; (c) acceleration of prechondrocyte and/or mesenchymal stem cell maturation; (d) enhancement of chondrocyte differentiation; and (e) chondrocyte proliferation acts on RANKL in the prechondrocytes and/or mesenchymal stem cells.
[3] The pharmaceutical composition used for treatment or prevention of chondropathies according to [1], wherein the compound that acts on the prechondrocytes and/or mesenchymal stem cells and induces at least one of: (a) acceleration of prechondrocyte and/or mesenchymal stem cell differentiation; (b) acceleration of prechondrocyte and/or mesenchymal stem cell proliferation; (c) acceleration of prechondrocyte and/or mesenchymal stem cell maturation; (d) enhancement of chondrocyte differentiation; and (e) chondrocyte proliferation is a compound selected from the group consisting of RANK, a mutant or a fragment peptide of RANK, a peptide structurally similar to RANK, a peptide structurally similar to a fragment peptide of RANK, a chemical substance structurally similar to RANK, a chemical substance structurally similar to a fragment peptide of RANK, OPG, a mutant or a fragment peptide of OPG, a peptide structurally similar to OPG, a peptide structurally similar to a fragment peptide of OPG, a chemical substance structurally similar to OPG, and a chemical substance structurally similar to a fragment peptide of OPG.
[4] The pharmaceutical composition used for treatment or prevention of chondropathies according to [2], wherein the compound that acts on the prechondrocytes and/or mesenchymal stem cells and induces at least one of: (a) acceleration of prechondrocyte and/or mesenchymal stem cell differentiation; (b) acceleration of prechondrocyte and/or mesenchymal stem cell proliferation; (c) acceleration of prechondrocyte and/or mesenchymal stem cell maturation; (d) enhancement of chondrocyte differentiation; and (e) chondrocyte proliferation is a compound selected from the group consisting of RANK, a mutant or a fragment peptide of RANK capable of acting on RANKL, a peptide structurally similar to RANK and capable of acting on RANKL, a peptide structurally similar to a fragment peptide of RANK and capable of acting on RANKL, a chemical substance structurally similar to RANK and capable of acting on RANKL, a chemical substance structurally similar to a fragment peptide of RANK and capable of acting on RANKL, OPG, a mutant or a fragment peptide of OPG capable of acting on RANKL, a peptide structurally similar to OPG and capable of acting on RANKL, a peptide structurally similar to a fragment peptide of OPG and capable of acting on RANKL, a chemical substance structurally similar to OPG and capable of acting on RANKL, and a chemical substance structurally similar to a fragment peptide of OPG capable of acting on RANKL.
[5] The pharmaceutical composition used for treatment or prevention of chondropathies according to [1] or [2], wherein the compound that acts on the chondrocytes and/or mesenchymal stem cells and induces at least one of: (a) acceleration of prechondrocyte and/or mesenchymal stem cell differentiation; (b) acceleration of prechondrocyte and/or mesenchymal stem cell proliferation; (c) acceleration of prechondrocyte and/or mesenchymal stem cell maturation; (d) enhancement of chondrocyte differentiation; and (e) chondrocyte proliferation is a peptide comprising the amino acid sequence as shown in SEQ ID NO: 7 or a salt thereof.
[6] The pharmaceutical composition used for treatment or prevention of chondropathies according to [1] or [2], wherein the compound that acts on the prechondrocytes and/or mesenchymal stem cells and induces at least one of: (a) acceleration of prechondrocyte and/or mesenchymal stem cell differentiation; (b) acceleration of prechondrocyte and/or mesenchymal stem cell proliferation; (c) acceleration of prechondrocyte and/or mesenchymal stem cell maturation; (d) enhancement of chondrocyte differentiation; and (e) chondrocyte proliferation is a fusion protein of a peptide comprising the amino acid sequence as shown in SEQ ID NO: 7 or a salt thereof and Flag represented by the amino acid sequence DYKDDDDK (SEQ ID NO: 16) or DYLDDDDL (SEQ ID NO: 17), GST, or an Fc region of IgG.
[7] The pharmaceutical composition used for treatment or prevention of chondropathies according to [1] or [2], wherein the compound that acts on the prechondrocytes and/or mesenchymal stem cells and induces at least one of: (a) acceleration of prechondrocyte and/or mesenchymal stem cell differentiation; (b) acceleration of prechondrocyte and/or mesenchymal stem cell proliferation; (c) acceleration of prechondrocyte and/or mesenchymal stem cell maturation; (d) enhancement of chondrocyte differentiation; and (e) chondrocyte proliferation is an anti-RANKL antibody or a functional fragment thereof.
[8] The pharmaceutical composition used for treatment or prevention of chondropathies according to any one of [1] to [7] comprising, as an active ingredient, a compound that acts on the prechondrocytes and/or mesenchymal stem cells and induces at least one of: (a) acceleration of prechondrocyte and/or mesenchymal stem cell differentiation; (b) acceleration of prechondrocyte and/or mesenchymal stem cell proliferation; (c) acceleration of prechondrocyte and/or mesenchymal stem cell maturation; (d) enhancement of chondrocyte differentiation; (e) chondrocyte proliferation; and (f) increased production of the cartilage matrix.
[9] An inducer of chondrocyte proliferation and differentiation comprising, as an active ingredient, a compound that acts on the prechondrocytes and/or mesenchymal stem cells and induces at least one of: (a) acceleration of prechondrocyte and/or mesenchymal stem cell differentiation; (b) acceleration of prechondrocyte and/or mesenchymal stem cell proliferation; (c) acceleration of prechondrocyte and/or mesenchymal stem cell maturation; (d) enhancement of chondrocyte differentiation; and (e) chondrocyte proliferation.
[10] The inducer of chondrocyte proliferation and differentiation according to [9], wherein the compound that acts on the prechondrocytes and/or mesenchymal stem cells and induces at least one of: (a) acceleration of prechondrocyte and/or mesenchymal stem cell differentiation; (b) acceleration of prechondrocyte and/or mesenchymal stem cell proliferation; (c) acceleration of prechondrocyte and/or mesenchymal stem cell maturation; (d) enhancement of chondrocyte differentiation; and (e) chondrocyte proliferation acts on RANKL in the prechondrocytes and/or mesenchymal stem cells.
[11] The inducer of chondrocyte proliferation and differentiation according to [9], wherein the compound that acts on the prechondrocytes and/or mesenchymal stem cells and induces at least one of: (a) acceleration of prechondrocyte and/or mesenchymal stem cell differentiation; (b) acceleration of prechondrocyte and/or mesenchymal stem cell proliferation; (c) acceleration of prechondrocyte and/or mesenchymal stem cell maturation; (d) enhancement of chondrocyte differentiation; and (e) chondrocyte proliferation is a compound selected from the group consisting of RANK, a mutant or a fragment peptide of RANK, a peptide structurally similar to RANK, a peptide structurally similar to a fragment peptide of RANK, a chemical substance structurally similar to RANK, a chemical substance structurally similar to a fragment peptide of RANK, OPG, a mutant or a fragment peptide of OPG, a peptide structurally similar to OPG, a peptide structurally similar to a fragment peptide of OPG, a chemical substance structurally similar to OPG, and a chemical substance structurally similar to a fragment peptide of OPG.
[12] The inducer of chondrocyte proliferation and differentiation according to [10], wherein the compound that acts on the prechondrocytes and/or mesenchymal stem cells and induces at least one of: (a) acceleration of prechondrocyte and/or mesenchymal stem cell differentiation; (b) acceleration of prechondrocyte and/or mesenchymal stem cell proliferation; (c) acceleration of prechondrocyte and/or mesenchymal stem cell maturation; (d) enhancement of chondrocyte differentiation; and (e) chondrocyte proliferation is a compound selected from the group consisting of RANK, a mutant or a fragment peptide of RANK capable of acting on RANKL, a peptide structurally similar to RANK and capable of acting on RANKL, a peptide structurally similar to a fragment peptide of RANK and capable of acting on RANKL, a chemical substance structurally similar to RANK and capable of acting on RANKL, a chemical substance structurally similar to a fragment peptide of RANK capable of acting on RANKL, OPG, a mutant or a fragment peptide of OPG capable of acting on RANKL, a peptide structurally similar to OPG and capable of acting on RANKL, a peptide structurally similar to a fragment peptide of OPG and capable of acting on RANKL, a chemical substance structurally similar to OPG and capable of acting on RANKL, and a chemical substance structurally similar to a fragment peptide of OPG capable of acting on RANKL.
[13] The inducer of chondrocyte proliferation and differentiation according to [9] or [10], wherein the compound that acts on the prechondrocytes and/or mesenchymal stem cells and induces at least one of: (a) acceleration of prechondrocyte and/or mesenchymal stem cell differentiation; (b) acceleration of prechondrocyte and/or mesenchymal stem cell proliferation; (c) acceleration of prechondrocyte and/or mesenchymal stem cell maturation; (d) enhancement of chondrocyte differentiation; and (e) chondrocyte proliferation is a peptide comprising the amino acid sequence as shown in SEQ ID NO: 7 or a salt thereof.
[14] The inducer of chondrocyte proliferation and differentiation according to [9] or [10], wherein the compound that acts on the prechondrocytes and/or mesenchymal stem cells and induces at least one of: (a) acceleration of prechondrocyte and/or mesenchymal stem cell differentiation; (b) acceleration of prechondrocyte and/or mesenchymal stem cell proliferation; (c) acceleration of prechondrocyte and/or mesenchymal stem cell maturation; (d) enhancement of chondrocyte differentiation; and (e) chondrocyte proliferation is a fusion protein of a peptide comprising the amino acid sequence as shown in SEQ ID NO: 7 or a salt thereof and Flag represented by the amino acid sequence DYKDDDDK (SEQ ID NO: 16) or DYLDDDDL (SEQ ID NO: 17), GST, or an Fc region of IgG.
[15] The inducer of chondrocyte proliferation and differentiation according to [9] or [10], wherein the compound that acts on the prechondrocytes and/or mesenchymal stem cells and induces at least one of: (a) acceleration of prechondrocyte and/or mesenchymal stem cell differentiation; (b) acceleration of prechondrocyte and/or mesenchymal stem cell proliferation; (c) acceleration of prechondrocyte and/or mesenchymal stem cell maturation; (d) enhancement of chondrocyte differentiation; and (e) chondrocyte proliferation is an anti-RANKL antibody or a functional fragment thereof.
[16] An agent for increasing cartilage matrix production comprising, as an active ingredient, a compound that acts on the prechondrocytes and/or mesenchymal stem cells and induces at least one of: (a) acceleration of prechondrocyte and/or mesenchymal stem cell differentiation; (b) acceleration of prechondrocyte and/or mesenchymal stem cell proliferation; (c) acceleration of prechondrocyte and/or mesenchymal stem cell maturation; (d) enhancement of chondrocyte differentiation; (e) chondrocyte proliferation; and (f) increased production of the cartilage matrix.
[17] The agent for increasing cartilage matrix production according to [16], wherein the compound that acts on the prechondrocytes and/or mesenchymal stem cells and induces at least one of: (a) acceleration of prechondrocyte and/or mesenchymal stem cell differentiation; (b) acceleration of prechondrocyte and/or mesenchymal stem cell proliferation; (c) acceleration of prechondrocyte and/or mesenchymal stem cell maturation; (d) enhancement of chondrocyte differentiation; (e) chondrocyte proliferation; and (f) increased production of the cartilage matrix acts on RANKL in the prechondrocytes and/or mesenchymal stem cells.
[18] The agent for increasing cartilage matrix production according to [16], wherein the compound that acts on the prechondrocytes and/or mesenchymal stem cells and induces at least one of: (a) acceleration of prechondrocyte and/or mesenchymal stem cell differentiation; (b) acceleration of prechondrocyte and/or mesenchymal stem cell proliferation; (c) acceleration of prechondrocyte and/or mesenchymal stem cell maturation; (d) enhancement of chondrocyte differentiation; (e) chondrocyte proliferation; and (f) increased production of the cartilage matrix is a compound selected from the group consisting of RANK, a mutant or a fragment peptide of RANK, a peptide structurally similar to RANK, a peptide structurally similar to a fragment peptide of RANK, a chemical substance structurally similar to RANK, a chemical substance structurally similar to a fragment peptide of RANK, OPG, a mutant or a fragment peptide of OPG, a peptide structurally similar to OPG, a peptide structurally similar to a fragment peptide of OPG, a chemical substance structurally similar to OPG, and a chemical substance structurally similar to a fragment peptide of OPG.
[19] The agent for increasing cartilage matrix production according to [17], wherein the compound that acts on the prechondrocytes and/or mesenchymal stem cells and induces at least one of: (a) acceleration of prechondrocyte and/or mesenchymal stem cell differentiation; (b) acceleration of prechondrocyte and/or mesenchymal stem cell proliferation; (c) acceleration of prechondrocyte and/or mesenchymal stem cell maturation; (d) enhancement of chondrocyte differentiation; (e) chondrocyte proliferation; and (f) increased production of the cartilage matrix is a compound selected from the group consisting of RANK, a mutant or a fragment peptide of RANK capable of acting on RANKL, a peptide structurally similar to RANK and capable of acting on RANKL, a peptide structurally similar to a fragment peptide of RANK and capable of acting on RANKL, a chemical substance structurally similar to RANK and capable of acting on RANKL, a chemical substance structurally similar to a fragment peptide of RANK capable of acting on RANKL, OPG, a mutant or a fragment peptide of OPG capable of acting on RANKL, a peptide structurally similar to OPG and capable of acting on RANKL, a peptide structurally similar to a fragment peptide of OPG and capable of acting on RANKL, a chemical substance structurally similar to OPG and capable of acting on RANKL, and a chemical substance structurally similar to a fragment peptide of OPG capable of acting on RANKL.
[20] The agent for increasing cartilage matrix production according to [16] or [17], wherein the compound that acts on the prechondrocytes and/or mesenchymal stem cells and induces at least one of: (a) acceleration of prechondrocyte and/or mesenchymal stem cell differentiation; (b) acceleration of prechondrocyte and/or mesenchymal stem cell proliferation; (c) acceleration of prechondrocyte and/or mesenchymal stem cell maturation; (d) enhancement of chondrocyte differentiation; (e) chondrocyte proliferation; and (f) increased production of the cartilage matrix is a peptide comprising the amino acid sequence as shown in SEQ ID NO: 7 or a salt thereof.
[21] The agent for increasing cartilage matrix production according to [16] or [17], wherein the compound that acts on the prechondrocytes and/or mesenchymal stem cells and induces at least one of: (a) acceleration of prechondrocyte and/or mesenchymal stem cell differentiation; (b) acceleration of prechondrocyte and/or mesenchymal stem cell proliferation; (c) acceleration of prechondrocyte and/or mesenchymal stem cell maturation; (d) enhancement of chondrocyte differentiation; (e) chondrocyte proliferation; and (f) increased production of the cartilage matrix is a fusion protein of a peptide comprising the amino acid sequence as shown in SEQ ID NO: 7 or a salt thereof and Flag represented by the amino acid sequence DYKDDDDK (SEQ ID NO: 16) or DYLDDDDL (SEQ ID NO: 17), GST, or an Fc region of IgG.
[22] The agent for increasing cartilage matrix production according to [16] or [17], wherein the compound that acts on the prechondrocytes and/or mesenchymal stem cells and induces at least one of: (a) acceleration of prechondrocyte and/or mesenchymal stem cell differentiation; (b) acceleration of prechondrocyte and/or mesenchymal stem cell proliferation; (c) acceleration of prechondrocyte and/or mesenchymal stem cell maturation; (d) enhancement of chondrocyte differentiation; (e) chondrocyte proliferation; and (f) increased production of the cartilage matrix is an anti-RANKL antibody or a functional fragment thereof.
[23] A pharmaceutical composition used for treatment or prevention of chondropathies comprising, as an active ingredient, a peptide comprising the amino acid sequence as shown in SEQ ID NO: 7 or a salt thereof.
[24] A pharmaceutical composition used for treatment or prevention of chondropathies comprising, as an active ingredient, a fusion protein of a peptide comprising the amino acid sequence as shown in SEQ ID NO: 7 or a salt thereof and Flag represented by the amino acid sequence DYKDDDDK (SEQ ID NO: 16) or DYLDDDDL (SEQ ID NO: 17), GST, or an Fc region of IgG.
[25] The pharmaceutical composition used for treatment or prevention of chondropathies according to [23] or [24], wherein the cartilage disease is selected from the group consisting of cartilage defect, osteochondritis dissecans, articular rheumatism, osteoarthritis, congenital cartilage disease, and cartilage injury.
[26] A method for screening for a compound that acts on the prechondrocytes and/or mesenchymal stem cells and induces at least one of: (a) acceleration of prechondrocyte and/or mesenchymal stem cell differentiation; (b) acceleration of prechondrocyte and/or mesenchymal stem cell proliferation; (c) acceleration of prechondrocyte and/or mesenchymal stem cell maturation; (d) enhancement of chondrocyte differentiation; and (e) chondrocyte proliferation,
the method comprising, when a candidate compound is brought into contact with RANKL-expressing prechondrocytes and/or mesenchymal stem cells and the candidate compound accelerates differentiation or proliferation of cells capable of differentiating into chondrocytes, determining that the candidate compound acts on the prechondrocytes and/or mesenchymal stem cells and induces at least one of: (a) acceleration of prechondrocyte and/or mesenchymal stem cell differentiation; (b) acceleration of prechondrocyte and/or mesenchymal stem cell proliferation; (c) acceleration of prechondrocyte and/or mesenchymal stem cell maturation; (d) enhancement of chondrocyte differentiation; and (e) chondrocyte proliferation.
[27] The screening method according to [26], wherein the compound that acts on the prechondrocytes and/or mesenchymal stem cells and induces at least one of: (a) acceleration of prechondrocyte and/or mesenchymal stem cell differentiation; (b) acceleration of prechondrocyte and/or mesenchymal stem cell proliferation; (c) acceleration of prechondrocyte and/or mesenchymal stem cell maturation; (d) enhancement of chondrocyte differentiation; and (e) chondrocyte proliferation acts on RANKL in the prechondrocytes and/or mesenchymal stem cells.
[28] The screening method according to [26] or [27], which screens for a compound that acts on the prechondrocytes and/or mesenchymal stem cells and induces at least one of: (a) acceleration of prechondrocyte and/or mesenchymal stem cell differentiation; (b) acceleration of prechondrocyte and/or mesenchymal stem cell proliferation; (c) acceleration of prechondrocyte and/or mesenchymal stem cell maturation; (d) enhancement of chondrocyte differentiation; (e) chondrocyte proliferation; and (f) increased production of the cartilage matrix,
the method comprising, when a candidate compound is brought into contact with RANKL-expressing prechondrocytes and/or mesenchymal stem cells and the candidate compound accelerates differentiation or proliferation of cells capable of differentiating into chondrocytes, determining that the candidate compound acts on the prechondrocytes and/or mesenchymal stem cells and induces at least one of: (a) acceleration of prechondrocyte and/or mesenchymal stem cell differentiation; (b) acceleration of prechondrocyte and/or mesenchymal stem cell proliferation; (c) acceleration of prechondrocyte and/or mesenchymal stem cell maturation; (d) enhancement of chondrocyte differentiation; (e) chondrocyte proliferation; and (f) increased production of the cartilage matrix.
[29] The pharmaceutical composition according to any one of [1] to [8], which further comprises at least one protein belonging to the TGF-β superfamily.
[30] The pharmaceutical composition according to [29], wherein the protein belonging to the TGF-βsuperfamily is TGF-β3 and/or BMP-2.
[31] The inducer of chondrocyte proliferation and differentiation according to any one of [9] to [15], which further comprises at least one protein belonging to the TGF-β superfamily.
[32] The inducer of chondrocyte proliferation and differentiation according to [31], wherein the protein belonging to the TGF-β superfamily is TGF-β3 and/or BMP-2.
[33] The agent for increasing cartilage matrix production according to any one of [16] to [22], which further comprises at least one protein belonging to the TGF-β superfamily.
[34] The agent for increasing cartilage matrix production according to [33], wherein the protein belonging to the TGF-β superfamily is TGF-β3 and/or BMP-2.
[35] The pharmaceutical composition according to any one of [23] to [25], which further comprises at least one protein belonging to the TGF-β superfamily.
[36] The pharmaceutical composition according to [35], wherein the protein belonging to the TGF-β superfamily is TGF-β3 and/or BMP-2.
This description includes part or all of the contents as disclosed in the descriptions and/or drawings of Japanese Patent Application Nos. 2008-254153 and 2008-314866, which are priority documents of the present application.
Hereafter, the present invention is described in detail.
RANKL (i.e., the receptor activator of NF-κB ligand) is a ligand of RANK (i.e., the receptor activator of NF-κB), which is a member of the TNF superfamily, and it is a type 2 transmembrane protein constituted an intracellular domain (a domain comprising amino acids 1 to 48 from the N-terminus of RANKL), a transmembrane domain, and an extracellular domain (JP Patent Publication (kohyo) No. 2002-509430 A; International Publication No. WO 98/46644 (currently U.S. Pat. No. 3,523,650). RANKL expressed on osteoblasts and osteoblastic progenitor cells by bone resorption factors. Osteoblastic progenitor cells indicated all cells capable of differentiating into osteoblasts. These cells are prechondrocytes, preosteoblastic cells, mesenchymal stem cells, interstitial cells, and myoblasts, which are capable of differentiating into osteoblasts. An extracelluar domain after 152 amino acids from the N-terminal site is the TNF ligand family homologous domain. SEQ ID NOs: 1 and 2 each show the full-length nucleotide sequence and amino acid sequence of human RANKL. SEQ ID NOs: 3 and 4 each show the full-length nucleotide sequence and amino acid sequence of RANK.
OPG (i.e., the osteoprotegerin) is a protein structurally similar to RANK and it is capable of acting on RANKL. SEQ ID NOs: 5 and 6 each show the full-length nucleotide sequence and amino acid sequence of OPG.
The present invention concerns a pharmaceutical composition containing an active ingredient, that is a compound acts on the prechondrocytes and/or mesenchymal stem cells and accelerate cartilage differentiation, proliferation, and maturation of such cells, enhance chondrocyte differentiation, induces chondrocyte proliferation, or increases cartilage matrix production; specifically, a compound that act on the prechondrocytes and/or mesenchymal stem cells and induces at least 1, 2, 3, 4, or all of the following: (a) acceleration of prechondrocyte and/or mesenchymal stem cell differentiation; (b) acceleration of prechondrocyte and/or mesenchymal stem cell proliferation; (c) acceleration of prechondrocyte and/or mesenchymal stem cell maturation; (d) enhancement of chondrocyte differentiation; (e) chondrocyte proliferation; and (f) increased production of the cartilage matrix. Combinations of two or more of (a) to (f) are (a) and (b); (a) and (c); (a) and (d); (a) and (e); (a) and (f); (b) and (c); (b) and (d); (b) and (e); (b) and (f); (c) and (d); (c) and (e); (c) and (f); (d) and (e); (d) and (f); (e) and (f); (a), (b), and (c); (a), (b), and (d); (a), (b), and (e); (a), (b), and (f); (a), (c), and (d); (a), (c), and (e); (a), (c), and (f); (a), (d), and (e); (a), (d), and (f); (a), (e), and (f); (a), (b), (c), and (d); (a), (b), (c), and (e); (a), (b), (c), and (f); (a), (b), (d), and (e); (a), (b), (d), and (f); (a), (b), (e), and (f); (a), (c), (d), and (e); (a), (c), (d), and (f); (a), (c), (e), and (f); (a), (d), (e), and (f); (b), (c), (d), and (e); (b), (c), (d), and (f); (b), (c), (e), and (f); (b), (d), (e), and (f); (c), (d), (e), and (f); (a), (b), (c), (d), and (e); (a), (b), (c), (d), and (f); (a), (b), (c), (e), and (f); (a), (b), (d), (e), and (f); (a), (c), (d), (e), and (f); (b), (c), (d), (e), and (f); and (a), (b), (c), (d), (e), and (f). An example of such pharmaceutical composition is a pharmaceutical composition containing an active ingredient, that is a compound acts on the prechondrocytes and/or mesenchymal stem cells and accelerates cartilage differentiation, proliferation, and maturation of such cells, enhances chondrocyte differentiation, induces cartilage proliferation, or increases cartilage matrix production. An example of an active ingredient is a compound that acts on RANKL, transmits a signal to the prechondrocytes and/or mesenchymal stem cells, and accelerates differentiation, proliferation, and maturation of such cells, enhances chondrocyte differentiation, induces chondrocyte proliferation, or increases cartilage matrix production. When such compounds acts on RANKL, the animal origin of RANKL on which such compounds can act is not limited, and RANKL with any animal origin, such as human RANKL, mouse RANKL, or rat RANKL, can be targeted. The term “[compound] acts on RANKL” used herein refers to a situation in which a compound acts on RANKL and transmits a signal to the prechondrocytes and/or mesenchymal stem cells. For example, a compound may bind to RANKL and transmit a signal to prechondrocytes and/or mesenchymal stem cells.
A compound that acts on RANKL, acts on the prechondrocytes and/or mesenchymal stem cells, and accelerates differentiation, proliferation, and maturation of such cells, enhances chondrocyte differentiation, induces chondrocyte proliferation, or increases cartilage matrix production may be any compound that acts on RANKL originating from any animal species. Examples of such compounds include a natural peptide, non-natural peptide, chemically-synthesized compound, or low-molecular-weight compounds derived from microorganism.
Examples of the compound indicated the present invention, which acts on the prechondrocytes and/or mesenchymal stem cells and accelerates differentiation, proliferation, and maturation of such cells, enhances chondrocyte differentiation, induces chondrocyte proliferation, or increases cartilage matrix production include a mutant or a fragment peptide of RANK, a peptide structurally similar to RANK, a peptide structurally similar to a fragment peptide of RANK, a chemical substance structurally similar to RANK, and a chemical substance structurally similar to a fragment peptide of RANK. Examples of these compound include RANK, a mutant or a fragment peptide of RANK capable of acting on RANKL, a peptide structurally similar to RANK and capable of acting on RANKL, a peptide structurally similar to a fragment peptide of RANK and capable of acting on RANKL, a chemical substance structurally similar to RANK and capable of acting on RANKL, and a chemical substance structurally similar to a fragment peptide of RANK capable of acting on RANKL.
The term “chemical substance” refers to a compound is except for a peptide or protein. RANK contains membrane RANK or soluble RANK. The term “membrane RANK” refers to RANK having a transmembrane region bound to a cell surface, and using a cell expressing natural RANK or a mammalian cell expressed recombinant RANK, or RANKFc. RANKFc is a fusion protein composing of an extracellular region of human RANK with a Fc region of human IgG (i.e., an Fc fusion protein).
According to the present invention, the term “structurally similarity” refers to similarity of partial structural conformations, capable of acting on RANKL, for example. Generally, a protein or peptide constituted the similar primary structure represented by an amino acid sequence, and a compound composed of a different amino acid sequence having a similar conformation and capable of acting on RANKL are included.
Further examples of compounds that act on prechondrocytes and/or mesenchymal stem cells and accelerate differentiation, proliferation, and maturation of such cells, enhance chondrocyte differentiation, induce chondrocyte proliferation, or increase cartilage matrix production include OPG, a mutant or a fragment peptide of OPG, a peptide structurally similar to OPG, a peptide structurally similar to a fragment peptide of OPG, a chemical substance structurally similar to OPG, and a chemical substance structurally similar to a fragment peptide of OPG. Examples of compounds that act on RANKL, act on the prechondrocytes and/or mesenchymal stem cells, and accelerate differentiation, proliferation, and maturation of such cells, enhance chondrocyte differentiation, induce chondrocyte proliferation, or increase cartilage matrix production include OPG, a mutant or a fragment peptide of OPG capable of acting on RANKL, a peptide structurally similar to OPG and capable of acting on RANKL, a peptide structurally similar to a fragment peptide of OPG and capable of acting on RANKL, a chemical substance structurally similar to OPG and capable of acting on RANKL, and a chemical substance structurally similar to a fragment peptide of OPG capable of acting on RANKL.
The term “chemical substance” refers to a compound except for a peptide or protein. OPG contains membrane OPG or soluble OPG. The term “membrane OPG” refers to OPG expressed on cell surface to bind' at the C-terminal region or the like. Cells expressing natural OPG, mammalian cells expressing recombinant OPG, or OPGFc can be used. OPGFc is a fusion protein of OPG with a Fc region of human IgG (i.e., an Fc fusion protein).
An example of an RANK or OPG analog includes a protein or a peptide comprising one or several point mutations of the amino acid sequence or a fragment peptide derived from RANK or OPG by deletion, substitution, or addition of amino acids and having the activity of RANK or OPG. The term “one or several” refers to 1 to 9, preferably 1 to 5, and more preferably 1 or 2.
An example of a peptide of RANK having a structure similar to that of a region binding to RANKL is a peptide comprising the amino acid sequence represented by SEQ ID NO: 7 (i.e., peptide D). This peptide is a cyclic peptide comprising a Cys 2-Cys 8 disulfide bond.
Further, a peptide salt of RANK having a structure similar to that of a region binding to RANKL can also be used. A peptide salt is not particularly limited, provided that it is pharmaceutically acceptable. Examples of peptide salts include acid addition salts and base addition salts. Examples of acid addition salts include organic acid salts, such as acetic acid salt, malic acid salt, succinic acid salt, trifluoroacetic acid (TFA) salt, tartaric acid salt, or citric acid salt and inorganic acid salts, such as hydrochloric acid salt, sulfuric acid salt, nitric acid salt, or phosphoric acid salt. Examples of base addition salts include alkali metals salt, such as sodium salt or potassium salt, alkaline earth metals salt, such as calcium salt or magnesium salt, and amines salt, such as ammonium salt or triethylamine salt. Among them, acetic acid salt is preferable, and acetic acid salt of the peptide comprising the amino acid sequence shown in SEQ ID NO: 7 is particularly preferable.
In addition, a fusion protein of a peptide having a structure similar to RANK capable of binding to RANKL with GST (glutathione-S-transferase) or a Fc region of human IgG (i.e., the GST fusion protein or the Fc fusion protein) can also be used. An example of such fusion protein is a fusion protein of peptide D with Flag represented by the amino acid sequence DYKDDDDK (SEQ ID NO: 16) or DYLDDDDL (SEQ ID NO: 17), GST (glutathione-S-transferase), or a Fc region of human IgG (i.e., the Flag fusion peptide D, the Fc fusion peptide D, or the GST fusion peptide D). Such fusion protein exhibits improved stability in vivo and its longer half-life in the blood. A fusion protein of GST or a fusion protein of Fc with other epitope tag can also be used. Examples of other epitope tag include a polyhistidine tag comprising 2 to 12, preferably 4 or more, more preferably 4 to 7, and further preferably 5 or 6 histidines, a FLAG tag, an Myc tag, a V5 tag, an Xpress tag, an HQ tag, an HA tag, an AU1 tag, a T7 tag, a VSV-G tag, a DDDDK tag, an S tag, a CruzTag09, a CruzTag22, a CruzTag41, a Glu-Glu tag, an Ha.11 tag, a KT3 tag, thioredoxin, a maltose-binding protein (MBP), and β galactosidase.
In the present invention, a compound that acts on RANKL, acts on the prechondrocytes and/or mesenchymal stem cells, and accelerates differentiation, proliferation, and maturation of such cells, enhances chondrocyte differentiation, induces chondrocyte proliferation, or increases cartilage matrix production is occasionally referred to as an agonist to RANKL.
In addition, such compounds contain an anti-RANKL antibody or a functional fragment antibody that acts on RANKL on the prechondrocytes and/or mesenchymal stem cells, and accelerates differentiation, proliferation, and maturation of such cells, enhances chondrocyte differentiation, induces chondrocyte proliferation, or increases cartilage matrix production. In the present invention, such an antibody is occasionally referred to as an agonist antibody to RANKL. An anti-RANKL antibody can be obtained as a polyclonal or monoclonal antibody by a known technique, with a monoclonal antibody being preferable. Examples of a monoclonal antibody include a monoclonal antibody produced by a hybridoma and a monoclonal antibody produced by a host that has been transformed by genetic engineering procedures with the use of an expression vector comprising the antibody gene. A monoclonal antibody-producing hybridoma can be produced by a known method as described below. Specifically, such hybridoma can be produced by carrying out immunization with the use of membrane-bound or soluble RANKL or a RANKL fragment peptide as a sensitized antigen by a known immunization method, fusing the resulting immunized cell with a known parent cell by a general cell fusion method, and screening for a monoclonal-antibody-producing cell by a known screening method. Upon immunization with RANKL, RANKL may be allowed to bind to a carrier protein such as bovine serum albumin (BSA), keyhole lympet haemocyanin, or the like before use. A monoclonal antibody that can be used is a recombinant monoclonal antibody produced by cloning the antibody gene with the use of a hybridoma, incorporating the cloned gene into an appropriate vector, and introducing the vector into a host by the gene recombinant technique (e.g., see Vandamme, A. M. et al., Eur. J. Biochem. 1990; 192: 767-775). In such case, it is possible to separately incorporate DNAs encoding the antibody heavy chain (H chain) and the light chain (L chain) into expression vectors for simultaneous transformation of a host cell. Alternatively, it is possible to incorporate DNA encoding the H chain and the L chain into a single expression vector for transformation of a host cell (see WO 94/11523). Also, it is possible to produce a recombinant antibody with the use of a transgenic animal. For instance, a fusion gene may be prepared by inserting the antibody gene into a non-terminal region of the gene encoding a protein peculiarly produced in milk (e.g., goat β-casein). A DNA fragment comprising the fusion gene into which the antibody gene has been inserted is injected into a goat embryo and the thus obtained embryo is introduced into a female goat. A desired antibody can be obtained from milk produced by a transgenic goat born from the goat into which the embryo had been introduced or by a progeny thereof (Ebert, K. M. et al., Bio/Technology 1994; 12: 699-702).
Examples of the anti-RANKL antibody of the present invention include a recombinant antibody that have been artificially modified so as to have reduced heteroantigenicity against humans, such as a chimeric antibody, a humanized antibody, and a human antibody, which can be produced by known methods. A chimeric antibody can be obtained by getting DNA encoding the antibody V region, ligating the DNA to DNA encoding the human antibody C region, incorporating the resultant into an expression vector, and introducing the vector into a host for antibody production. A humanized antibody is referred to as reconstituted (reshaped) human antibody in some cases. A humanized antibody is obtained by transplanting the complementary determining region (CDR) of a non-human mammal antibody such as a mouse antibody into the complementary determining region of a human antibody. It can be produced by known methods (see EP 125023 and WO96/02576). The C-region of a chimeric antibody and that of a humanized antibody are used as the C region of a chimeric antibody and of a humanized antibody, respectively, and a Cγ1, Cγ2, Cγ3, or Cγ4 H chain and a Cκ or Cλ L chain can be used, for example. Further, in order to improve the stability of an antibody or production stability, the human antibody C region may be modified.
A human antibody can be obtained by administering an antigen to a transgenic animal having the ability to produce a human-derived antibody that has been imparted via introduction of, for example, a human antibody gene locus. An example of such transgenic animal is a mouse, and a method for preparing a mouse capable of producing a human antibody is described in, for example, WO 02/43478.
The term “anti-RANKL antibody” includes not only a complete antibody but also a functional fragment of an antibody. A functional fragment of an antibody corresponds to a part of an antibody (i.e., a partial fragment) having at least one action of the antibody on a relevant antigen. Specific examples thereof include F (ab′)2, Fab′, Fab, Fv, disulfide-bound Fv, single chain Fv (scFv), and a polymer thereof (D. J. King, Applications and Engineering of Monoclonal Antibodies, 1998, T. J. International Ltd.).
In addition, when a monoclonal antibody is used, a single type of monoclonal antibody may be used alone. Two or more types, for example, 2, 3, 4, or 5 types of monoclonal antibodies each recognizing a different epitope, may be used.
It is possible to determine whether or not the above compound has agonist activity that promotes signal transmission through RANKL, for example, administering an antibody to prechondrocytes and/or mesenchymal stem cells capable of expressing RANKL, allowing the antibody to act on RANKL, and examining if differentiation, proliferation, or generation of cartilage, or increase cartilage matrix production. Differentiation and proliferation can be determined using the elevated expression level of the α1 chain of type II collagen in the cell, for example. Since the cartilage matrix is stained alcian blue, whether or not the cartilage is generated and cartilage matrix production is increased can be determined by alcian blue staining.
Furthermore the present invention concerns a pharmaceutical composition comprising a compound that acts on the prechondrocytes and/or mesenchymal stem cells and accelerates cartilage differentiation, proliferation, and maturation of such cells, enhances chondrocyte differentiation, induces chondrocyte proliferation, or increases cartilage matrix production; i.e., a compound that acts on the prechondrocytes and/or mesenchymal stem cells and induces at least 1, 2, 3, 4, or all of the following: (a) acceleration of prechondrocyte and/or mesenchymal stem cell differentiation; (b) acceleration of prechondrocyte and/or mesenchymal stem cell proliferation; (c) acceleration of prechondrocyte and/or mesenchymal stem cell maturation; (d) enhancement of chondrocyte differentiation; (e) chondrocyte proliferation; and (f) increased production of the cartilage matrix in combination with at least one protein belonging to the TGF-β superfamily. Administration of such compound in combination with at least one protein belonging to the TGF-β superfamily can lead synergistic effects on: (a) acceleration of prechondrocyte and/or mesenchymal stem cell differentiation; (b) acceleration of prechondrocyte and/or mesenchymal stem cell proliferation; (c) acceleration of prechondrocyte and/or mesenchymal stem cell maturation; (d) enhancement of chondrocyte differentiation; (e) chondrocyte proliferation; and (f) increased production of the cartilage matrix or effects of increasing cartilage matrix production.
Examples of proteins belonging to the TGF-β superfamily indicate the BMP family including BMP2, 4, 7, the growth and differentiation factors (GDF)-5, 6, and 7, and the TGF family including activin, inhibin, TGF-α, TGF-β1 to β3, and the latent transforming growth factor protein (LTBP) (Bilezilian et al., Principles of Bone Biology, Third Edition, Chapter 53). Several ones of these factors can be used in combination. For example, the above compound can be used in combination with TGF-β3 and/or BMP-2.
The composition of the present invention being capable of enhancing chondrogenesis or increasing cartilage matrix production can be used as a research reagent in vitro, and a pharmaceutical composition in vivo.
The pharmaceutical composition in the present invention can be used as a pharmaceutical composition that enhances chondrogenesis or increases cartilage matrix production. Examples of target cartilage include hypertrophic cartilage (growth cartilage) and permanent cartilage (articular cartilage). The pharmaceutical composition in the present invention is an inducer of chondrocyte proliferation and differentiation or a chondrogenesis enhancer. Also, the pharmaceutical composition in the present invention can be used for prevention or treatment of a chondropathies. Examples of chondropathies include cartilage defects caused by external injuries or surgical treatment, osteochondritis dissecans, articular rheumatism, osteoarthritis, congenital chondropathies (achondrogenesis), and cartilage injury (e.g., medial meniscus injury). Examples of target test animals include mammalian animals, such as humans, bovines, horses, pigs, sheep, goats, cats, dogs, rabbits, rats, and mice.
A dose of the pharmaceutical composition in the present invention varies depending on symptoms, age, body weight, and other conditions. In general, a dose is approximately 0.01 mg to 10,000 mg per adult per day in the case of oral administration, and such amount of the pharmaceutical composition can be administered once or several separate times. In the case of parenteral administration, the pharmaceutical composition can be administered locally to the location of damaged or lost cartilage or to the cartilage of a patient having one of the above chondropathies.
The pharmaceutical composition in present invention can comprise a carrier, a diluent, and an excipient that are generally used in the field of formulations. For example, lactose, magnesium stearate, and the like can be used as carriers or excipients for tablets. Examples of an injectable aqueous liquid that can be used include a physiological salt solution and an isotonic solution comprising glucose and other adjuvants. Such injectable aqueous liquid can be used in combination with an appropriate solubilizing agent such as alcohol, polyalcohol (e.g., propylene glycol), or a nonionic surface active agent. Examples of an oily liquid that can be used include sesame oil and soybean oil. Such oily liquid can be used in combination with a solubilizing agent such as benzyl benzoate or benzyl alcohol.
The present invention further concerns a method for screening of a compound that acts on the prechondrocytes and/or mesenchymal stem cells and accelerates differentiation, proliferation, and maturation of such cells, enhances chondrocyte differentiation, induces chondrocyte proliferation, or increases cartilage matrix production; for example, a compound that acts on RANKL, acts on the prechondrocytes and/or mesenchymal stem cells, and accelerates differentiation, proliferation, and maturation of such cells, enhances chondrocyte differentiation, induces chondrocyte proliferation, or increases cartilage matrix production.
In the screening method of the present invention, a candidate compound is added to the prechondrocytes and/or mesenchymal stem cells, and determined whether or not the candidate compound accelerates differentiation of the above cells. For example, a candidate compound can be added to cells having properties similar to the prechondrocytes and/or mesenchymal stem cells, and determined whether or not the candidate compound acts on RANKL and accelerates differentiation and proliferation of the above cells. Differentiation can be measured the elevated expression level of α1-chain of type II collagen in the cells or detected by alcian blue staining. When a candidate compound accelerates proliferation of these cells, it can be determined that the candidate compound is a compound that acts on the prechondrocytes and/or mesenchymal stem cells and accelerates differentiation, proliferation, and maturation of such cells, accelerates chondrocyte differentiation, induces chondrocyte proliferation, or increases cartilage matrix production; that is, a compound that acts on RANKL, acts on the prechondrocytes and/or mesenchymal stem cells, and accelerates differentiation, proliferation, and maturation of such cells, enhances chonrrocyte differentiation, induces chondrocyte proliferation, or increases cartilage matrix production.
Also, a candidate compound can be administered to a mouse, for example, topically to a C57BL/6CrjCrlj mouse, determined whether or not chondrocyte proliferation is observed, and the result may be used to determine that the candidate compound acts on the prechondrocytes and/or mesenchymal stem cells and accelerates differentiation, proliferation, and maturation of such cells, enhances chondrocyte differentiation, induces chondrocyte proliferation, or increases cartilage matrix production; that is, a compound that acts on RANKL, acts on the prechondrocytes and/or mesenchymal stem cells, and accelerates differentiation, proliferation, and maturation of such cells, enhances chondrocyte differentiation, induces chondrocyte proliferation, or increases cartilage matrix production.
The present invention is described in greater detail with reference to the following examples, although the technical scope of the present invention is not limited thereto.
A synthetic peptide was used for the experiment. Synthetic peptide D is a peptide comprising the amino acid sequence as shown in SEQ ID NO: 7, it is composed of 9 amino acid residues, and it is a cyclic peptide comprising two cysteine residues bound by a disulfide bond. It is reported that synthetic peptide D binds to RANKL (Aoki et al., J. Clin. Invest., 116: 1525, 2006).
Human mesenchymal stem cells were purchased from Lonza. A maintenance medium was purchased from Lonza.
Human mesenchymal stem cells were seeded at 5×104 cells/well in 48-well plate (IWAKI). The culture supernatant was removed 24 hours later, the medium was replaced with a chondrocyte differentiation induction medium (Lonza), and the medium was replaced with fresh medium every 3 or 4 days. Simultaneously, peptide D was added at 100 μM (the group to which peptide D was administered). Further, a group cultured with 100 μM peptide D and 1 ng/ml BMP-4 (R&D) was examined. BMP-4 was added at 1 ng/ml as a positive control group. After 14 days, these cells were fixed in 10% neutral buffered formalin. After fixation, the cells were stained with an alcian blue solution for 4 hours, and the culture plate was photographed. Moreover the pigment was eluted using a 6M guanidinium hydrochloride solution from the culture plate. The eluate (100 μl) was moved to a new 96-well plate, and measured the absorbance at 620 nm by microplate reader (BMG Labtech).
Alcian blue solution (pH 2.5)
Alcian blue 8GX: 1 g
Acetic acid: 3 ml
Distilled water: 97 ml
In
The culture cells (ATDC5) derived from a mouse chondrogenic EC (embryonal carcinoma) cell was provided by Professor Hiraki and Associate Professor Shukunami in the Institute for Frontier Medical Sciences, Kyoto University. DMEM/F-12 medium (Cellgro) containing 5% FBS (Nichirei) was used as a maintenance medium.
ATDC5 cells were seeded at 2×104 cells/well in a 48-well plate (IWAKI). The culture supernatant was removed 24 hours later, and DMEM/F-12 medium containing 10 ng/ml insulin (Roche) and transferrin (Roche) were added. The medium was replaced with fresh medium every 3 or 4 days.
Simultaneously, peptide D was added at 25 μM and 100 μM. One ng/ml and 5 ng/ml BMP-4 (R&D) were added as positive control. In order to examine the synergistic effects of peptide D and BMP-4, further, 25 μM peptide D and 1 ng/ml BMP-4 were added. After 14 days, these cells were fixed in 10% neutral buffered formalin. After fixation, the cells were stained with an alcian blue solution for 4 hours, and the culture plate was photographed.
Formation of alcian blue positive nodules was observed with the addition of peptide D in ATDC5 cells, and the number thereof increased in a dose dependent manner (
The synergistic effects between peptide D and BMP-4 were not observed in ATDC5 cells.
Mouse prechondrocytes, ATDC5 cells (5×104 cells) were seeded in a 6-cm dish (IWAKI) and cultured in the presence of a cartilage differentiation induction medium containing 10 ng/ml insulin and transferrin for 7 days and for 14 days. The peptide D group was added at 200 μM peptide D, and 5 ng/ml of BMP-4 was added to the positive control group. The cells were washed with PBS after culture, the cells were dissolved in 1 ml TRIZOL (Qiagen), and the solution was obtained. After 5 min at room temperature, 0.2 ml of chloroform (Wako) was added, followed by vigorous inversion mixing and centrifugation at 4° C. and 12,000×g for 15 minutes. The supernatant was collected in a new tube, and was added to 0.5 ml of isopropanol (Nacalai), followed by inversion mixing. The resultant was left at room temperature for 10 minutes and centrifuged at 4° C. and 12,000×g for 10 minutes. The supernatant was discarded, and the resultant was added to 70% ethanol. After dry-up, RNA was dissolved in 87.5 μl of DEPC water, 10 μl of RDD buffer and 2.5 μl of DNase, and the mixture was allowed to stand at room temperature for 10 minutes. The RNA sample was cleaned by the RNeasy MinElute Cleanup Kit (Qiagen), and the concentration of the obtained RNA was measured using NanoDrop. The obtained RNA (250 ng) was electrophoresed on 1% agarose gel, checked degradation of RNA, and undegradated RNA samples (250 ng each) were used in RT-PCR. RT-PCR was carried out using the ThermoScript RT-PCR System (Invitrogen) and random primers.
After cDNA was synthesized, PCR was carried out using primers specific for the α1 chains of mouse type II collagen (mCol 2α1), mouse type X collagen (mCol X), and mouse aggrecan (mAggrecan). PCR was carried out using mouse GAPDH-specific primers for standardization. The sequences of PCR primers used are shown below. PCR was carried out under the conditions described below with the use of Ex Taq™ Hot Start Version (Takara Bio Inc.).
The α1 chain of mouse type II collagen (mCol 2α1) was subjected to initial thermal denaturation at 95° C. for 3 minutes, followed by 37 cycles of 95° C. for 10 seconds, 48° C. for 15 seconds, and 68° C. for 30 seconds, and an elongation reaction at 68° C. for 10 minutes.
Mouse type X collagen (mCol X) was subjected to initial thermal denaturation at 95° C. for 3 minutes, followed by 34 cycles of 95° C. for 10 seconds, 54° C. for 15 seconds, and 68° C. for 30 seconds, and an elongation reaction at 68° C. for 10 minutes.
Mouse aggrecan (mAggrecan) was subjected to initial thermal denaturation at 95° C. for 3 minutes, followed by 40 cycles of 95° C. for 10 seconds, 54° C. for 15 seconds, and 68° C. for 30 seconds, and an elongation reaction at 68° C. for 10 minutes.
Mouse GAPDH was subjected to initial thermal denaturation at 95° C. for 3 minutes, followed by 23 cycles of 94° C. for 10 seconds, 58° C. for 15 seconds, and 68° C. for 30 seconds, and an elongation reaction at 68° C. for 10 minutes.
mCol X, was subjected to 37 cycles on day 14 and the resulting data was obtained.
The sample obtained after PCR was electrophoresed on 2% agarose gel, and a specific band was detected by UV with the use of ethidium bromide staining (
As a result, the aggrecan expression level was increased on day 7 in ATDC5 cells treated with peptide D, and the expression level of the α chain of type II collagen was significantly increased compared with the control (
The peptide described in Example 1 was used. The ATDC5 cells described in Example 2 were used as cultured cells. The ATDC5 cells were seeded in a 6-cm dish (IWAKI) at 1×105 cells/well. The culture supernatant was removed 72 hours later, and DMEM/F-12 medium containing 10 ng/ml insulin (Roche) and 10 ng/ml transferrin (Roche) was added. The medium was replaced with fresh medium every 3 or 4 days.
Simultaneously, peptide D was added at 100 μM. The medium was removed 4 days and 7 days after the induction of differentiation. The cells were washed with PBS, and RNA of these cells was obtained using the Absolutely RNA Miniprep Kit (Stratagene) 7 days after the induction of differentiation. The extracted RNA was subjected to GeneChip analysis (Affimetrix, Kurabo). The expression levels of factors that were significantly increased or decreased with the addition of peptide D were calculated by the ratio of signal value treated with peptide D divided by the signal value of the control group.
The results are shown in
Further, expression of asporin, IGFbp2, IGFbp6, and ADAMTS5 that have been reported to be involved in the progression of osteoarthritis was inhibited with the addition of peptide D. Thus, it was confirmed that the ATDC5 cells were differentiated into chondrocytes with the addition of peptide D.
The ATDC5 cells described in Example 2 were used as cultured cells. The anti-RANKL monoclonal antibodies mmB (clone 12A668, Santa Cruz), 1-12H (clone 1-12H, Oriental Yeast Co., Ltd.), mh2 (clone 70513, R&D), sc55 (clone 4i167, Santa Cruz), and sc72 (clone 500-M46, Santa Cruz) and the monoclonal antibody FL317 (Santa Cruz) were used. As a positive control sample, 2×10−4 M FGF2 (Fiblast Spray, Kaken Pharmaceutical Co., Ltd.) was used.
The ATDC5 cells (4×103 cells) were seeded in a 96-well plate, and the medium was replaced with a serum-free medium after the cells had adhered. The antibodies were added at 5 μg/ml 16 hours later. Ten μl of WST-1 (Roche) was added per 100 μl of the solution after 72 hours culture, and the absorbance at 450 nm (reference wavelength: 595 nm) was measured using a microplate reader with the elapse of time for 1 to 4 hours at 37° C.
As a result, the ATDC5 proliferation activity was significantly increased with the addition of the anti-RANKL polyclonal antibody FL317 and the anti-RANKL monoclonal antibodies 1-1211, mmB, and mh2 (
The ATDC5 cells described in Example 2 were used as cultured cells. The mmB antibody described in Example 5 and the anti-RANKL monoclonal antibody mmC (clone 12A380, ALEXIS) were used.
The ATDC5 cells were seeded in a 48-well plate (IWAKI) at 2×104 cells/well. The culture supernatant was removed 72 hours later, the medium was replaced with the differentiation induction medium described in Example 5, and the medium was replaced with fresh medium every 3 or 4 days. Simultaneously, the mmB antibody and the mmC antibody were added at 0.5 μg/ml, on day 14 these cells were fixed in 10% neutral buffered formalin. After fixation, alcian blue staining was carried out in the manner described in Example 2, and nodule formation was observed.
The results are shown in
The peptide described in Example 1 was used. Human mesenchymal stem cells were purchased from Lonza. A maintenance medium was purchased from Lonza. Three-dimensional culture of human mesenchymal stem cells
Chondrocytes are three-dimensionally cultured induce dedifferentiation. Three dimensional culture system relatively reflected the natural conditions. Human mesenchymal stem cells were seeded at 2.5×105 cells in 15-ml tubes (TPP) and the cells were collected by centrifuged at 1,000 rpm and room temperature for 4 minutes. The supernatant was removed and the medium was replaced with 0.5 ml chondrocyte differentiation induction medium (Lonza) with 10 ng/ml TGF-β3 (R&D). The medium was replaced with fresh medium every 3 or 4 days. Simultaneously, peptide D was added at 50 μM and at 150 μM (i.e., a low-dose peptide D group and a high-dose peptide D group). After 14 days, the cells were fixed in 4% PFA (Wako), photographed under a microscope (
Subsequently, the synergistic effects of peptide D and TGF-β3 on cartilage formation were examined. 2.5×105 human mesenchymal stem cells were cultured in the presence of 40 μM peptide D and 10 ng/ml TGF-β3 with cartilage differentiation induction medium for 21 days. After the pellets were fixed in 4% PFA, the pellet was photographed under a microscope (
Moreover, the synergistic effects of peptide D and BMP-2 were examined. 2.5×105 human mesenchymal stem cells were cultured in the presence of 40 μM peptide D and 100 ng/ml BMP-2 (R&D) with cartilage differentiation induction medium for 21 days. After the pellets were fixed in 4% PFA, the pellet was photographed under a microscope (
Reagent/cultured cells
The peptide described in Example 1 was used. Human mesenchymal stem cells were purchased from Lonza. A maintenance medium was purchased from Lonza.
Human mesenchymal stem cells were seeded in a 6-well plate (Nunc) at 1×105 cells/well, the culture supernatant was discarded 96 hours later, and 2 ml of a cartilage differentiation induction medium was added. The control group, the 40 μM peptide D group, the 10 ng/ml TGF-β3 group, and the 40 μM peptide D+10 ng/ml TGFβ3 group were prepared. Each culture medium was replaced 24 hours after the stimulation. The cells were dissolved in 1 ml of TRIZOL (Invitrogen) 96 hours after the stimulation, and RNA was isolated. The isolated RNA was used for GeneChip analysis (Affimetrix, Kurabo). The expression levels of factors that were significantly increased or decreased with the addition of the peptide D, TGF-β3, or peptide D+TGF-β3 were calculated by the ratio of signal values treated with peptide D, TGF-β3, and peptide D+TGF-β3 divided by the signal value of the control group. The results are shown in
The expression level of the aggrecan as the cartilage matrix was elevated 24 hours after the addition of peptide D, and the elevated expression level was maintained 96 hours after the addition. In contrast, the aggrecan expression level of the TGF-β3 group was equivalent to that of the control group 24 hours after the addition, but the aggrecan expression level had become lower than that of the control group 96 hours after the addition. The aggrecan expression level in the peptide D+TGF-β3 group was lowered because of the influence of lowered expression caused by TGF-β3. Also, the expression levels of Sox9 (SRY (sex determining region Y)-box 9) involved in chondrocyte differentiation were elevated in the three groups (peptide D, TGF-β3, and peptide D+TGF-β3) 24 hours and 96 hours after the addition, compared with the control group. Peptide D elevated IGF2R and versican expression 24 hours later, and elevated IGF-1, LTBP2, and TGFβ1 expression levels 96 hours later.
The abbreviations used in
ACAN: aggrecan
IGF1: insulin growth factor 1 LTBP2: latent transforming growth factor protein 2
SOX9: SRY (sex determining region Y)-box 9
As described in Examples, prechondrocytes and mesenchymal stem cells are differentiated into chondrocytes, such cells are proliferated, or the cartilage matrices are increased by the molecules that act on membrane RANKL, such as membrane RANK, a RANK analog peptide, an anti-RANKL antibody, soluble RANK, OPG, a mutant thereof, or an analog thereof.
A compound, such as membrane RANK, a RANK analog peptide, an anti-RANKL antibody, soluble RANK, OPG, a mutant thereof, an analog thereof, or a natural or a synthetic low-molecular-weight compound, that acts on the prechondrocytes and/or mesenchymal stem cells and accelerates differentiation, proliferation, and maturation of such cells, enhances chondrocyte differentiation, induces chondrocyte proliferation, or increases cartilage matrix production, for example, a molecule acting on RANKL induces differentiation and proliferation of chondrocytes can be used as a pharmaceutical product for prevention or treatment of a chondropathies. Screening for a compound that acts on prechondrocytes and/or mesenchymal stem cells and accelerates differentiation, proliferation, and maturation of such cells, enhances chondrocyte differentiation, induces chondrocyte proliferation, or increases cartilage matrix production, for example, a molecule acting on RANKL was obtained a compound can be applied to research and development of novel inducers of chondrocyte differentiation and proliferation and agents for increasing cartilage matrix production.
SEQ ID NO: 7: Synthetic peptide
SEQ ID NOs: 16 and 17: Tag sequences
All publications, patents, and patent applications cited herein are incorporated herein by reference in their entirety.
| Number | Date | Country | Kind |
|---|---|---|---|
| 2008-254153 | Sep 2008 | JP | national |
| 2008-314866 | Dec 2008 | JP | national |
| Filing Document | Filing Date | Country | Kind | 371c Date |
|---|---|---|---|---|
| PCT/JP2009/066060 | 9/9/2009 | WO | 00 | 3/30/2011 |
